Digestive and Liver Disease
Volume 44, Issue 2 , Pages 95-105 , February 2012

New treatment strategies in advanced neuroendocrine tumours

  • Thomas Walter

      Affiliations

    • Fédération des Spécialités Digestives, Hôpital Edouard Herriot, Lyon CEDEX 03, France
    • Corresponding Author InformationCorresponding author at: Pavillon H, Hôpital Edouard Herriot, 69437 Lyon CEDEX 03, France.
    • ,
  • Hedia Brixi-Benmansour

      Affiliations

    • Service d’Hépato-Gastroentérologie et d’Oncologie Digestive, CHU Reims, Hôpital Robert Debré, Reims CEDEX, France
    • ,
  • Catherine Lombard-Bohas

      Affiliations

    • Fédération des Spécialités Digestives, Hôpital Edouard Herriot, Lyon CEDEX 03, France
    • ,
  • Guillaume Cadiot

      Affiliations

    • Service d’Hépato-Gastroentérologie et d’Oncologie Digestive, CHU Reims, Hôpital Robert Debré, Reims CEDEX, France

Received 19 July 2011 ,Accepted 23 August 2011.

  • Image Result

    Management algorithm for patients with (a) advanced neuroendocrine tumours (NETs) of the gastrointestinal tract, (b) or with advanced pancreatic NETs. Abbreviations: mTOR: mammalian target of rapamyci

    Management algorithm for patients with (a) advanced neuroendocrine tumours (NETs) of the gastrointestinal tract, (b) or with advanced pancreatic NETs. Abbreviations: mTOR: mammalian target of rapamycin; PPI: proton pump inhibitor; RFA: radiofrequency ablation; TAE: transarterial embolization.

PII: S1590-8658(11)00331-8

doi: 10.1016/j.dld.2011.08.022

Digestive and Liver Disease
Volume 44, Issue 2 , Pages 95-105 , February 2012

Article Tools

* Image Usage & Resolution